AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

March 18, 2024

Study Completion Date

March 18, 2024

Conditions
Opioid Abuse
Interventions
BEHAVIORAL

Overdose Notification

We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

Northwestern University

OTHER

collaborator

AltaMed Health Services Corporation

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

University of Southern California

OTHER